Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation
Not available.
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2024-12-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11872 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126404505174016 |
|---|---|
| author | Shuangyou Liu Lihong An Zhichao Yin Yuehui Lin Zhuojun Ling Biping Deng Xinjian Yu Qinlong Zheng Defeng Zhao Tong Wu Alex H. Chang Chunrong Tong |
| author_facet | Shuangyou Liu Lihong An Zhichao Yin Yuehui Lin Zhuojun Ling Biping Deng Xinjian Yu Qinlong Zheng Defeng Zhao Tong Wu Alex H. Chang Chunrong Tong |
| author_sort | Shuangyou Liu |
| collection | DOAJ |
| description |
Not available.
|
| format | Article |
| id | doaj-art-25ae541029c742f7bf4223d02647f2db |
| institution | Kabale University |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-25ae541029c742f7bf4223d02647f2db2024-12-12T19:43:05ZengFerrata Storti FoundationHaematologica0390-60781592-87212024-12-01999110.3324/haematol.2024.286534Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantationShuangyou Liu0Lihong An1Zhichao Yin2Yuehui Lin3Zhuojun Ling4Biping Deng5Xinjian Yu6Qinlong Zheng7Defeng Zhao8Tong Wu9Alex H. Chang10Chunrong Tong11Department of Hematology, Beijing Gobroad Boren Hospital, BeijingDepartment of Hematology, Beijing Gobroad Boren Hospital, BeijingDepartment of Hematology, Beijing Gobroad Boren Hospital, BeijingDepartment of Hematology, Beijing Gobroad Boren Hospital, BeijingDepartment of Hematology, Beijing Gobroad Boren Hospital, BeijingCytology Laboratory, Beijing Gobroad Boren Hospital, BeijingMedical Laboratory, Beijing Gobroad Boren Hospital, BeijingMedical Laboratory, Beijing Gobroad Boren Hospital, BeijingDepartment of Hematology, Beijing Gobroad Boren Hospital, BeijingDepartment of Bone Marrow Transplantation, Beijing Gobroad Boren Hospital, BeijingShanghai YaKe Biotechnology Ltd., ShanghaiDepartment of Hematology, Beijing Gobroad Boren Hospital, Beijing Not available. https://haematologica.org/article/view/11872 |
| spellingShingle | Shuangyou Liu Lihong An Zhichao Yin Yuehui Lin Zhuojun Ling Biping Deng Xinjian Yu Qinlong Zheng Defeng Zhao Tong Wu Alex H. Chang Chunrong Tong Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation Haematologica |
| title | Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation |
| title_full | Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation |
| title_fullStr | Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation |
| title_full_unstemmed | Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation |
| title_short | Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation |
| title_sort | five year outcomes of cd19 followed by cd22 chimeric antigen receptor t cell therapy in b cell acute lymphoblastic leukemia patients who relapsed after allo transplantation |
| url | https://haematologica.org/article/view/11872 |
| work_keys_str_mv | AT shuangyouliu fiveyearoutcomesofcd19followedbycd22chimericantigenreceptortcelltherapyinbcellacutelymphoblasticleukemiapatientswhorelapsedafterallotransplantation AT lihongan fiveyearoutcomesofcd19followedbycd22chimericantigenreceptortcelltherapyinbcellacutelymphoblasticleukemiapatientswhorelapsedafterallotransplantation AT zhichaoyin fiveyearoutcomesofcd19followedbycd22chimericantigenreceptortcelltherapyinbcellacutelymphoblasticleukemiapatientswhorelapsedafterallotransplantation AT yuehuilin fiveyearoutcomesofcd19followedbycd22chimericantigenreceptortcelltherapyinbcellacutelymphoblasticleukemiapatientswhorelapsedafterallotransplantation AT zhuojunling fiveyearoutcomesofcd19followedbycd22chimericantigenreceptortcelltherapyinbcellacutelymphoblasticleukemiapatientswhorelapsedafterallotransplantation AT bipingdeng fiveyearoutcomesofcd19followedbycd22chimericantigenreceptortcelltherapyinbcellacutelymphoblasticleukemiapatientswhorelapsedafterallotransplantation AT xinjianyu fiveyearoutcomesofcd19followedbycd22chimericantigenreceptortcelltherapyinbcellacutelymphoblasticleukemiapatientswhorelapsedafterallotransplantation AT qinlongzheng fiveyearoutcomesofcd19followedbycd22chimericantigenreceptortcelltherapyinbcellacutelymphoblasticleukemiapatientswhorelapsedafterallotransplantation AT defengzhao fiveyearoutcomesofcd19followedbycd22chimericantigenreceptortcelltherapyinbcellacutelymphoblasticleukemiapatientswhorelapsedafterallotransplantation AT tongwu fiveyearoutcomesofcd19followedbycd22chimericantigenreceptortcelltherapyinbcellacutelymphoblasticleukemiapatientswhorelapsedafterallotransplantation AT alexhchang fiveyearoutcomesofcd19followedbycd22chimericantigenreceptortcelltherapyinbcellacutelymphoblasticleukemiapatientswhorelapsedafterallotransplantation AT chunrongtong fiveyearoutcomesofcd19followedbycd22chimericantigenreceptortcelltherapyinbcellacutelymphoblasticleukemiapatientswhorelapsedafterallotransplantation |